Compare ACNT & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACNT | HURA |
|---|---|---|
| Founded | 1945 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.5M | 131.8M |
| IPO Year | N/A | N/A |
| Metric | ACNT | HURA |
|---|---|---|
| Price | $16.49 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 68.5K | ★ 620.5K |
| Earning Date | 11-04-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $171,413,000.00 | N/A |
| Revenue This Year | $22.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $173.13 | ★ N/A |
| Revenue Growth | ★ 65.05 | N/A |
| 52 Week Low | $10.76 | $0.70 |
| 52 Week High | $16.84 | $5.50 |
| Indicator | ACNT | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 70.39 | 26.25 |
| Support Level | $15.75 | $0.70 |
| Resistance Level | $16.22 | $0.85 |
| Average True Range (ATR) | 0.39 | 0.10 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 79.73 | 11.79 |
Ascent Industries Co is a specialty chemicals platform focused on the development, production, and distribution of tailored, performance-driven chemical solutions. It has one reportable segment: Specialty Chemicals. The Specialty Chemicals segment includes the operating results of the Company's plants involved in the production of specialty chemicals and produces critical ingredients and process aids for the oil & gas, household, industrial and institutional (HII), personal care, coatings, adhesives, sealants and elastomers (CASE), pulp and paper, textile, automotive, agricultural, water treatment, construction and other industries.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.